Trial Profile
Effects of NEPA (novel combination of netupitant and palonosetron) on ECG of healthy volunteers: A randomized, controlled, thorough ECG trial.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2013
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary) ; Moxifloxacin
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions
- 19 Jun 2013 New trial record
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.